Published October 29, 2026
Something genuinely historic just happened in the compounding world. On October 28, 2026, the U.S. Department of Health and Human Services (HHS), together with the FDA, issued an Interim Access Policy for Compounding Using Certain Peptides. For the first time, the federal government has signaled that state-licensed 503A compounding pharmacies can prepare six specific peptides for individual patients, by prescription, without the threat of federal enforcement hanging over every order.
The six peptides covered are BPC-157, TB-500, KPV, MOTS-c, Epitalon, and Semax.
At Restorative Compounding Pharmacy, we have followed this story closely from the first advisory committee vote this summer, and we have been preparing for this exact moment. Here is what the policy actually says, what it means for patients, and why where you source these peptides matters more now than it ever has.
What Actually Changed on October 28
Let's be precise, because precision protects patients. The new HHS policy is a form of enforcement discretion. The government is stating that it does not intend to take action against a state-licensed pharmacy or a licensed physician who compounds these six peptides for a specific patient, as long as a defined set of conditions is met.
This is a real, meaningful opening. It is also important to understand what it is not:
It is not FDA approval. None of these six peptides is an FDA-approved drug, and this policy does not make them one.
It does not cover "research-use-only" powders, gray-market vials, or products sold as dietary supplements. The only lawful path it recognizes is a prescription filled by a licensed pharmacy.
It is interim. It stays in place while the FDA works through formal rulemaking on each peptide, and it can be refined over time.
In other words: the door that just opened is a pharmacy door. The patient sees a provider, the provider writes a patient-specific prescription, and a licensed compounding pharmacy prepares the medication to professional standards. That is exactly the channel this policy is built around, and exactly the channel Restorative operates in every single day.
How We Got Here
This did not happen overnight. In July 2026, the FDA's Pharmacy Compounding Advisory Committee reviewed seven peptides and voted to recommend six of them for the 503A bulk substances list. HHS leadership has publicly supported broadening responsible access to peptides, and this interim policy is the first concrete federal step toward turning those recommendations into real, legal patient access.
We want to acknowledge the work that went into getting here. We are grateful to HHS and the FDA for recognizing what clinicians and patients have been saying for years: that there is a real therapeutic interest in these compounds, and that the safest way to meet it is through the licensed, regulated compounding system, not the unregulated internet. Thoughtful access, built on quality and oversight, is a win for everyone.
The Six Peptides, and What They're Explored For
Each of these peptides has a following among clinicians working in recovery, longevity, metabolic health, and wellness. Research is still developing, and none is FDA-approved, so a licensed provider should always determine whether any of them is appropriate for you. Here is a plain-language overview:
BPC-157: a peptide studied for its potential role in tissue repair, gut health, and musculoskeletal recovery.
TB-500 (a thymosin beta-4 fragment): explored for recovery, tissue repair, and flexibility, often alongside BPC-157.
KPV: a small anti-inflammatory tripeptide derived from alpha-MSH, studied for inflammatory conditions of the gut and skin.
MOTS-c: a mitochondrial-derived peptide investigated for metabolic health, energy, and exercise capacity.
Epitalon: a peptide studied in the context of longevity, cellular aging, and sleep and circadian rhythm.
Semax: explored for cognitive function, focus, and neuroprotection.
How Restorative Can Now Compound These Peptides Under 503A
As a licensed 503A compounding pharmacy, Restorative is built for exactly this kind of individualized, prescription-based medicine. Under the new interim policy, when a licensed provider determines that one of these six peptides is appropriate and writes a patient-specific prescription, our pharmacy team can compound it to order: the right peptide, the right strength, the right dosage form, for one patient at a time.
That patient-specific model is the heart of 503A compounding, and it is the heart of this policy. We are not mass-producing anonymous vials for a website checkout cart. We are preparing a prescribed medication for a named patient under the care of a licensed clinician, with a pharmacist's oversight at every step.
We're Ramping Up Production, Responsibly
We have been preparing for this. As the policy took shape over the summer and fall, we invested in the sourcing, formulation work, and quality systems needed to offer these peptides the right way from day one. Now that the interim policy is in effect, we are scaling our capacity to meet demand, while refusing to cut a single corner on quality.
Ramping up, to us, does not mean rushing. It means expanding the parts of our operation that keep patients safe: verified ingredient sourcing, validated compounding processes, and the testing and documentation that stand behind every preparation we dispense. Growth without quality is exactly the problem this policy is meant to solve. We intend to be part of the solution.
This Is Access at Its Finest
For years, patients who were curious about these peptides faced a frustrating choice: go without, or roll the dice on an unregulated online seller shipping "research chemicals" of unknown origin and purity. Neither option served anyone well.
What this policy creates is a third path, and it is the right one. A patient can now have a real conversation with a licensed provider, receive a legitimate prescription if it is appropriate, and have that prescription filled by a licensed pharmacy that stands behind what it makes. That is access the way it should work: clinician-guided, pharmacist-prepared, and accountable. This is access at its finest.
Why Sourcing From a Quality Compounding Pharmacy Matters
Here is the part we cannot say loudly enough. A peptide is only as good as the hands that make it. The same molecule can be a carefully tested, sterile, accurately dosed medication, or a contaminated, mislabeled, mystery powder, depending entirely on who prepared it and how.
This is not hypothetical. Regulators have already linked serious illnesses, including hospitalizations, to compounded injectables made with supplement-grade ingredients and poor sterility controls. When something goes into your body, especially by injection, the quality of the pharmacy is not a detail. It is the whole ballgame.
When you source from a licensed compounding pharmacy like Restorative, you get:
Ingredients purchased from vetted, documented suppliers, not anonymous marketplaces.
Preparation by licensed pharmacy professionals under state board oversight.
A real prescription tied to a real provider who knows your history.
Accountability: a licensed business with its name, license, and reputation on every label.
Rigorous Testing Standards Are Everything
Quality compounding is not a slogan. It is a set of hard standards, and testing is where those standards are proven. For sterile peptide preparations, that means attention to the things patients never see but absolutely depend on:
Potency and identity: confirming the preparation contains the correct peptide at the correct strength.
Sterility: verifying that injectable preparations are free of microbial contamination.
Endotoxin control: guarding against the bacterial toxins that have caused real harm in poorly made products.
Documentation and traceability: so every preparation can be stood behind, start to finish.
These are the standards that separate a legitimate pharmacy from a gray-market seller. They are the reason the interim policy centers on licensed pharmacies in the first place. And they are non-negotiable at Restorative.
The Gray Market's Days Are Numbered
For too long, unregulated "research-use-only" sellers have filled the vacuum left by a lack of legitimate access. They operate with disclaimers instead of accountability, and patients have borne the risk. That era is ending.
Two forces are closing the gap at the same time. On one side, the FDA has sharply increased enforcement against online peptide vendors and the "research chemical" loophole. On the other, this interim policy finally gives patients and providers a legitimate, licensed alternative. When there is a safe, legal, high-quality path, the excuse for the gray market disappears, and so, increasingly, will the gray market itself. We think that is exactly as it should be.
Interested in Compounded Peptides? Here's Your Next Step
If you or your provider are interested in any of these six peptides, the path is simple and legitimate: talk with a licensed provider about whether one of them fits your goals and health history, and have them send the prescription to Restorative. Our pharmacy team will take it from there: prepared to order, tested, and dispensed with the quality you deserve.
Frequently Asked Questions
Did the FDA approve these six peptides?
No. The October 28, 2026 HHS interim policy is enforcement discretion, not FDA approval. None of the six peptides is an FDA-approved drug. The policy means the government does not intend to take action against licensed pharmacies and providers who compound them for individual patients under the stated conditions, while the FDA works through formal rulemaking.
Which peptides are covered?
Six: BPC-157, TB-500, KPV, MOTS-c, Epitalon, and Semax. A seventh peptide reviewed at the same time was not recommended.
Do I need a prescription?
Yes. The entire point of this policy is a prescription-based, patient-specific channel through a licensed pharmacy. You will need a prescription from a licensed provider. Products sold online as "research use only" or as supplements are not covered by this policy.
Is this the same as buying peptides online?
Not at all. Unregulated online "research chemical" sellers operate outside this policy and outside the law. A compounded prescription from a licensed pharmacy is prepared for you specifically, by licensed professionals, with quality testing behind it.
Can Restorative compound these now?
Yes. As a licensed 503A compounding pharmacy, Restorative can prepare these six peptides to order when a licensed provider writes a patient-specific prescription. We have been preparing for this and are scaling capacity while holding our quality standards firm.
Could this policy change?
Possibly. Because it is interim, the policy stays in place while the FDA completes formal rulemaking, and its details can be refined over time. We monitor these developments closely and will keep our patients and partners informed.
This article is for general educational purposes and is not medical advice. The six peptides discussed are not FDA-approved drugs; the October 2026 HHS policy is interim enforcement discretion for compounding by licensed pharmacies under defined conditions. Whether any peptide is appropriate for you is a decision for you and a licensed healthcare provider. Compounded medications are prepared pursuant to a valid prescription.
